Baird lowered the firm’s price target on Biogen (BIIB) to $250 from $255 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results where its beat was driven by MS as its launch products are showing slow growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen’s Balanced Risk-Reward Scenario: Hold Rating Amidst Strong Legacy Performance and Strategic Challenges
- Biogen Inc. Reports Strong Q3 2025 Results
- Biogen’s Resilient Performance and Growth Prospects Justify Buy Rating
- Morning Movers: Alphabet, Eli Lilly rise following quarterly results
- Biogen’s Strong Financial Performance and Strategic Positioning Justify Buy Rating